Achillion Pharmaceuticals (ACHN) Sell Rating Reiterated at Chardan Capital Markets Amid ACH-4471 Risks

November 3, 2016 11:16 AM EDT
Get Alerts ACHN Hot Sheet
Price: $4.06 +2.27%

Rating Summary:
    14 Buy, 3 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade ACHN Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Chardan Capital Markets analyst Madhu Kumar reiterated a Sell rating and $5 price target on Achillion Pharmaceuticals (NASDAQ: ACHN) saying ACH-4471 liver signals and developmental delays pose risks.

Kumar commented, "This morning, Achillion Pharmaceuticals (Sell) announced 3Q16 earnings results and updates on clinical programs. Regarding the phase I multiple ascending dose (MAD) trial for ACH-4471, a small molecule inhibitor of complement factor D for the treatment of complement diseases such as paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulonephritis (C3G), the company announced "[t]wo cases of self-limited, ALT elevations (Grade 3 and 4) were
observed post-treatment in the mid- and high dose groups, respectively." Achillion further announced that interim results from the
phase I trial will be presented 1H17."

The analyst said Liver enzyme elevations in healthy volunteers create safety risks in an already competitive complement therapy
space. In addition, continued delays in healthy volunteers portend more significant delays in the PNH setting.

For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.

Shares of Achillion Pharmaceuticals closed at $6.04 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA

Related Entities

Earnings, Chardan Capital Markets

Add Your Comment